Anchorage, ALASKA3 Active Studies

Diffuse Large B-Cell Lymphoma Clinical Trials in Anchorage, ALASKA

Find 3 actively recruiting diffuse large b-cell lymphoma clinical trials in Anchorage, ALASKA. Connect with local research sites and explore new treatment options.

3
Active Trials
2
Sponsors
2,080
Enrolling

Recruiting Diffuse Large B-Cell Lymphoma Studies in Anchorage

About Diffuse Large B-Cell Lymphoma Clinical Trials in Anchorage

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of cases. It is an aggressive lymphoma that grows rapidly. Treatment usually involves chemoimmunotherapy, with CAR-T cell therapy for relapsed cases.

There are currently 3 diffuse large b-cell lymphoma clinical trials recruiting participants in Anchorage, ALASKA. These studies are seeking a combined 2,080 participants. Research is being sponsored by Hoffmann-La Roche, Celgene. Clinical trial participation is free and participants receive study-related medical care at no cost.

Diffuse Large B-Cell Lymphoma Clinical Trials in Anchorage — FAQ

Are there diffuse large b-cell lymphoma clinical trials in Anchorage?

Yes, there are 3 diffuse large b-cell lymphoma clinical trials currently recruiting in Anchorage, ALASKA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Anchorage?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Anchorage research site will contact you about next steps.

Are clinical trials in Anchorage free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Anchorage studies also compensate for your time and travel.

What diffuse large b-cell lymphoma treatments are being tested?

The 3 active trials in Anchorage are testing new therapies including novel drugs, biologics, and treatment approaches for diffuse large b-cell lymphoma.

Data updated March 2, 2026 from ClinicalTrials.gov